Decode the G‑BA
Strengten your Global Market Access Strategy
First-hand German reimbursement expertise, combined with an international health-system perspective, for pharmaceutical and biotech leaders making high-stakes decisions in rare disease, orphan drugs, and advanced therapies.
Shape your clinical development strategy with future reimbursement in mind.
Drawing on my first-hand experience within the G-BA and my background in international health and health policy, I help pharmaceutical and biotech leaders evaluate their options, anticipate reimbursement considerations, and make better-informed decisions from development through market access.
Through MBM Future Health, I provide independent strategic advice on G-BA, AMNOG, German reimbursement, and broader market-access challenges.
I provide tailored strategic advice on the G-BA procedures and reimbursement decisions relevant to your medicine.
Your unique benefits
G-BA Expertise
You benefit from my long-standing experience at the G‑BA.
Your Personal Expert
Work directly with a senior expert throughout your engagement.
Lean Operations
You align your efforts with G‑BA expectations.
High Value
Your resources are allocated effectively.
Orphan Drug Specialist
Operating Worldwide
About
Meriem Bouslouk-Marx, MBM Future Health
Dr. Meriem Bouslouk-Marx
G‑BA and AMNOG strategy
Orphan-drug and rare-disease reimbursement strategy
Cell and Gene Therapy
Joint Scientific Consultation preparation
Medical background
International health-system and access assessments
Expert Speaker
Coming together is a beginning.
Keeping together is progress.
Working together is success.
Henry Ford
Get in touch via LinkedIn:
